| DC45858 |
Cav 2.2 blocker 2 |
Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid. |
|
| DC46482 |
CALP3 TFA |
CALP3 TFA, a Ca2+-like peptide, is a potent Ca2+ channel blocker that activates EF hand motifs of Ca2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca2+]i by modulating the activity of Calmodulin (CaM), Ca2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia. |
|
| DC46858 |
Norverapamil D7 hydrochloride |
Norverapamil D7 ((±)-Norverapamil D7) hydrochloride is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor. |
|
| DC46983 |
Ziconotide acetate |
Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research. |
|
| DC47716 |
(-)-Denudatin B |
(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels. And (-)-Denudatin B has nonspecific antiplatelet action |
|
| DC47937 |
Nemadipine-A |
Nemadipine-A is a specific inhibitor of the EGL-19 L-type Ca2+ channel. Nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand. |
|
| DC48188 |
HSK16149 |
HSK16149 is a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit. |
|
| DC48189 |
Xestospongin C |
Xestospongin C ((-)-Xestospongin C) is a selective, reversible inositol 1,4,5-trisphosphate receptor (IP3R) inhibitor. Xestospongin C acts as an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) pump of internal stores. Xestospongin C blocks IP3-induced Ca2+ release from cerebellar microsomes with an IC50 of 358 nM. Xestospongin C is a valuable tool for investigating the structure and function of IP3Rs and Ca2+ signaling in neuronal and nonneuronal cells. |
|
| DC48478 |
L-Phenylalanine-13C9,15N |
L-Phenylalanine-13C9,15N ((S)-2-Amino-3-phenylpropionic acid-13C9,15N) is the 13C- and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals. |
|
| DC48480 |
L-Phenylalanine-13C9 |
L-Phenylalanine-13C9 ((S)-2-Amino-3-phenylpropionic acid-13C9) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals. |
|
| DC49120 |
L-Phenylalanine-13C6 |
L-Phenylalanine-13C6 ((S)-2-Amino-3-phenylpropionic acid-13C6) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals. |
|
| DC49360 |
L-Phenylalanine-3-13C |
L-Phenylalanine-3-13C ((S)-2-Amino-3-phenylpropionic acid-3-13C) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals. |
|
| DC49692 |
T-Type calcium channel inhibitor(TTA-P2)
Featured
|
T-Type calcium channel inhibitor is a potent inhibitor of T-Type calcium channel. T-Type calcium channel inhibitor penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. T-Type calcium channel inhibitor has the potential for the research of neurology disease. |
|
| DC49693 |
TTA-P1 |
TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy. |
|
| DC70379 |
Efonidipine hydrochloride monoethanolate |
Efonidipine (NZ-105) is a potent, dual T-type and L-type calcium channel blocker, exhibits antihypertensive effect through vasodilatation; increases coronary blood flow by blocking L & T-type calcium channels and attenuates myocardial ischaemia, lowers blood pressure in cerebral resistance vessels and prevents hypertension induced brain damage; increases glomerular filtration rate without increasing intra-glomerular pressure and filtration fraction. |
|
| DC70394 |
Etripamil |
Etripamil (MSP-2017) is a novel intranasal non-dihydropyridine calcium channel blocker that has begun phase III clinical trials for the treatment of paroxysmal supraventricular tachycardias. |
|
| DC70877 |
USP5-Cav3.2 inhibitor II-1 |
USP5-Cav3.2 inhibitor II-1 is a small molecule inhibitor of USP5-Cav3.2 interaction, without affecting the enzymatic activity of USP5.II-1 inhibited both phases of formalin-induced nocifensive behaviors in mice.Cav3.2 is required for the action of II-1.II-1 also mediated a robust inhibition of mechanical allodynia induced by injury to the sciatic nerve. |
|
| DC70883 |
VK-II-86
Featured
|
VK-II-86 is a carvedilol analogue lacking antagonist activity at β-adrenoceptors, effectively suppresses SOICR by directly reducing the open duration of the cardiac ryanodine receptor (RyR2).VK-II-86 exhibited >2,000-fold lower beta-AR binding affinity than carvedilol.VK-II-86 prevented stress-induced ventricular tachyarrhythmias in RyR2-mutant mice and did so more effectively when combined with either of the selective beta blockers metoprolol or bisoprolol.VK-II-86 prevented hypokalaemia-induced AP prolongation and depolarization but did not alter AP parameters in normokalaemia. |
|
| DC70968 |
Fenoverine |
Fenoverine is an antispasmodic drug and inhibits calcium channel currents. Fenoverine induces rhabdomyolysis. |
|
| DC71360 |
Cav 2.2/3.2 blocker 1 |
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS. |
|
| DC71361 |
MONIRO-1 |
MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. |
|
| DC71797 |
CXL-1020 |
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure. |
|
| DC71798 |
IAA65 |
IAA65 is a potent T-type calcium channel inhibitor with a IC50 value of 18.9 µM. IAA65 can be used for epilepsy research. |
|
| DC71799 |
IAB15 |
IAB15 is a potent T-type calcium channel inhibitor. IAB15 can be used for epilepsy research. |
|
| DC72047 |
Fasudil dihydrochloride |
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca2+ channel antagonist and vasodilator. |
|
| DC72651 |
SG-094
Featured
|
SG094 is a potent TPC2 inhibitor with antiproliferative effects. SG-094 can be used for the research of cancer. |
|
| DC73594 |
2E151 |
2E151 is a small molecule calcium channel activator, increases murine antigen-specific antibody responses when used as a co-adjuvant with LPS. |
|
| DC73595 |
2D216 |
2D216 is a small molecule calcium channel activator, increases murine antigen-specific antibody responses when used as a co-adjuvant with LPS. |
|
| DC73596 |
Efonidipine hydrochloride |
Efonidipine (NZ-105) is a potent, dual T-type and L-type calcium channel blocker, exhibits antihypertensive effect through vasodilatation. |
|
| DC73597 |
Extracellular vesicle enhancer 634 |
Extracellular vesicle enhancer 634 (Compound 634) is a small molecule enhancer of extracellular vesicle (EV) release with immunostimulatory potency via induction of Ca2+ influx, which is mediated by store-operated Ca2+ entry (SOCE). |
|
